In 2012, the NeoSphere trial demonstrated that the pathological complete response rate of the neoadjuvant therapy of pertuzumab combined with trastuzumab and docetaxel achieved a significantly higher rate than the single trastuzumab group; the CLEOPATRA trial demonstrated that pertuzumab + trastuzumab + chemotherapy in the treatment of patients with metastatic HER2-positive breast cancer extended the median OS and reduced the risk of death compared with the control group [46,47]. Here, ERBB2 is linked to breast carcinoma.